FDA granted priority review for atezolizumab (MPDL3280A) for the treatment of people with locally advanced or metastatic non-small cell lung cancer whose disease expresses the protein PD-L1, as determined by an FDA-approved test, and who have progressed on or after platinum-containing chemotherapy. “In a study of atezolizumab in people with previously treated advanced lung cancer,...
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
